Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF: insights from the STEP-HFpEF programme

13 May 2024 (08:42 - 08:50)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Mark C Petrie

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail

Effect of IV iron in patients with heart failure with preserved ejection fraction

Professor S. von Haehling (Goettingen, DE)

Presentation thumbnail

Discussant review - FAIR-HFpEF

Professor P. Kalra (Portsmouth, GB)

Presentation thumbnail

Discussant review - STEP HFpEF Program

Professor A. Bayes Genis (Badalona, ES)

Presentation thumbnail

Design and baseline characteristics of REALIZE K: a placebo-controlled randomized-withdrawal trial of sodium zirconium cyclosilicate for hyperkalaemia management in patients with HF and reduced EF

Doctor M. Kosiborod (Kansas City, US)

Presentation thumbnail

Discussant review - REALIZE-K

Professor G. Rosano (London, GB)

Access the full session

Session thumbnail

Late breaking clinical trials: further analyses and baseline characteristics

The Event

Event poster

Heart Failure 2024

13 May 2024 08:42 CET

You may be interested in

Congress Presentation

The benefits of weight loss in heart failure: is it the weight loss or the drug?

Congress Presentation

STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity

Congress Presentation

What's the next step in HFpEF?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources